Skip to main content
Figure 1 | BMC Infectious Diseases

Figure 1

From: Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients

Figure 1

a) No difference was found in the 100-day survival between the patients of group A, who were started on a caspofungin-based combination therapy within < 7 days from diagnosis of IA vs the patients of group B, who were started on a caspofungin-based combination therapy after 7 days from diagnosis of IA. b) and c) Kaplan-Meier estimate of 100-day survival and OS according to the timing of diagnosis of IA: IA after diagnosis of underlying disease vs IA after HSCT vs IA after relapse.

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us